Zevra Therapeutics Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Neil McFarlane

Chief Executive Officer (CEO)

US$3.4m

Compensación total

Porcentaje del salario del CEO	4.6%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	1.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Neil McFarlane en comparación con los beneficios de Zevra Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$3m	US$158k	-US$46m

Compensación vs. Mercado: La compensación total de Neil($USD3.45M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD705.42K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Neil con los resultados de la empresa.

CEO

Neil McFarlane (50 yo)

less than a year

Permanencia

US$3,445,231

Compensación

Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He has served as Director at Collegi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Neil McFarlane	President	less than a year	US$3.45m	sin datos
Christal M. Mickle	Co-Founder & Chief Development Officer	no data	US$1.67m	0.065% $ 131.1k
R. Clifton	CFO, Secretary & Treasurer	8.9yrs	US$2.26m	0.038% $ 76.5k
Joshua Schafer	Chief Commercial Officer & Executive VP of Business Development	1.3yrs	US$1.82m	0.0084% $ 16.9k
Sven Guenther	Chief Scientific Officer	1.3yrs	US$1.08m	0.0066% $ 13.2k
Nichol Ochsner	Vice President of Investor Relations & Corporate Communications	1.8yrs	sin datos	sin datos
Christopher Lauderback	Senior Vice President of Manufacturing	1.3yrs	sin datos	sin datos
Rene Braeckman	Senior Vice President of Clinical Development	1.3yrs	sin datos	sin datos
Daniel Gallo	Senior Vice President of Medical Affairs & Advocacy	1.3yrs	sin datos	sin datos
Adrian Quartel	Chief Medical Officer	less than a year	sin datos	sin datos
Timothy Sangiovanni	Senior VP & Corporate Controller	7.3yrs	sin datos	0.011% $ 21.4k

1.3yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1GDA no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Neil McFarlane	President	less than a year	US$3.45m	sin datos
Wendy Dixon	Independent Director	1.1yrs	US$274.00k	0% $ 0
Douglas Calder	Independent Director	1.1yrs	US$258.02k	0% $ 0
Tamara Favorito	Independent Chair	2.8yrs	US$324.39k	0.0017% $ 3.5k
Donald Jasinski	Member of Scientific and Medical Advisory Board	no data	sin datos	sin datos
John Bode	Independent Director	1.1yrs	US$264.31k	0.048% $ 96.3k
Corey Watton	Independent Director	1.1yrs	US$260.67k	0.0024% $ 4.8k
Barney Bishop	Chairman of Scientific and Medical Advisory Board	17.3yrs	sin datos	sin datos
Robert Findling	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
Jeffrey Gudin	Co-Chair of Physician Advisory Council	10.6yrs	sin datos	sin datos
Srinivas Nalamachu	Co-Chair of Physician Advisory Council	10.6yrs	sin datos	sin datos
Thomas Anderson	Independent Director	less than a year	US$243.04k	0.024% $ 48.2k

1.1yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de 1GDA no se considera experimentada (1 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Zevra Therapeutics Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Zevra Therapeutics, Inc., Annual General Meeting, May 13, 2024

Zevra Therapeutics, Inc. Appoints Alvin Shih to the Board of Directors

Zevra Therapeutics, Inc. Announces Executive Changes

Zevra Therapeutics, Inc. Announces Board Changes

High number of new directors

Zevra Therapeutics, Inc. Announces Change of CEO, Effective June 1, 2023

Recent updates

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.34 loss in 1Q 2023)

Zevra Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Zevra Therapeutics, Inc., Annual General Meeting, May 13, 2024

Full year 2023 earnings released: US$1.30 loss per share (vs US$1.21 loss in FY 2022)

Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia

Zevra Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast breakeven date pushed back to 2026

Zevra Therapeutics, Inc. Appoints Alvin Shih to the Board of Directors

Zevra Therapeutics, Inc. Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Zevra Therapeutics, Inc. Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

New minor risk - Shareholder dilution

No longer forecast to breakeven

Zevra Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zevra Therapeutics, Inc. Announces Executive Changes

Zevra Therapeutics, Inc. Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of Sdx, the Sole Active Pharmaceutical Ingredient in Kp1077, in Healthy Volunteers At Psych Congress 2023

New minor risk - Profitability

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.70 loss in 2Q 2022)

No longer forecast to breakeven

Zevra Therapeutics, Inc. Announces Board Changes

High number of new directors

First quarter 2023 earnings released: US$0.34 loss per share (vs US$0.054 loss in 1Q 2022)

Zevra Therapeutics, Inc. Announces Change of CEO, Effective June 1, 2023

Full year 2022 earnings released: US$1.21 loss per share (vs US$2.11 loss in FY 2021)

KemPharm, Inc. Appoints Daniel Gallo as Senior Vice President of Medical Affairs and Advocacy

KemPharm, Inc., Annual General Meeting, Apr 25, 2023

KemPharm, Inc. Announces Promotion of Sven Guenther to Chief Scientific Officer and Christal Mickle to Chief Product Development Officer

KemPharm, Inc. Appoints Richard W. Pascoe, as Chief Executive Officer

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

KemPharm, Inc. Appoints Christopher Posner as New Independent Director

KemPharm, Inc. Announces That the U.S. Food and Drug Administration (The FDA) Grants the Orphan Drug Designation to Serdexmethylphenidate

Third quarter 2022 earnings released: US$0.19 loss per share (vs US$0.05 loss in 3Q 2021)

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.19 loss per share (vs US$0.05 loss in 3Q 2021)

Kempharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (Sdx)

Second quarter 2022 earnings released: US$0.70 loss per share (vs US$0.40 loss in 2Q 2021)

Forecast breakeven date pushed back to 2024

KemPharm, Inc.(NasdaqGS:KMPH) dropped from Russell Microcap Value Index

First quarter 2022 earnings released: US$0.054 loss per share (vs US$2.49 loss in 1Q 2021)

KemPharm, Inc., Annual General Meeting, Jun 28, 2022

KemPharm, Inc. Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

Forecast breakeven date pushed back to 2023

Kempharm, Inc. Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate

Forecast breakeven date pushed back to 2023

Full year 2021 earnings released: US$2.11 loss per share (vs US$3.21 loss in FY 2020)

KemPharm, Inc. Completes KP1077 Pre-IND Meeting Process with FDA

KemPharm, Inc. (NasdaqGS:KMPH) announces an Equity Buyback for $50 million worth of its shares.

Kempharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose Sdx”

Forecast to breakeven in 2022

Third quarter 2021 earnings released: US$0.05 loss per share (vs US$0.68 loss in 3Q 2020)

Forecast breakeven pushed back to 2023

Second quarter 2021 earnings released: US$0.37 loss per share (vs US$0.21 profit in 2Q 2020)

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc

Forecast breakeven pushed back to 2022

Forecast breakeven pushed back to 2022

Insider recently bought €71k worth of stock

Forecast breakeven moved forward to 2021

Full year 2020 earnings released: US$3.21 loss per share (vs US$13.23 loss in FY 2019)

Revenue beats expectations

KemPharm, Inc. to Report Q4, 2020 Results on Mar 11, 2021

KemPharm Announces FDA Approval of AZSTARYS™ (Serdexmethylphenidate and Dexmethylphenidate Capsules, for Oral Use, CII), A New Once-Daily Treatment for ADHD

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad